News Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-06 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-1.57%		-3.85%	-21.38%

May. 30	Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	CI
May. 24	Cyclo Therapeutics Files $100 Million Mixed Shelf	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	May. 31	AQ
Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	May. 30	CI
Cyclo Therapeutics Files $100 Million Mixed Shelf	May. 24	MT
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 16	BU
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Cyclo Therapeutics : Corporate Presentation	May. 02	PU
HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	May. 01	MT
Cyclo Therapeutics : Corporate Presentation	Apr. 18	PU
Cyclo Therapeutics : Corporate Presentation	Mar. 18	PU
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Mar. 18	BU
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	Mar. 15	AQ
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	Mar. 14	MT
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	Mar. 14	BU
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	Jan. 30	AQ
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office	Jan. 29	BU
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K	Dec. 28	PU
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	Dec. 27	MT
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.	Dec. 27	BU
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	Dec. 27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Summary

Filters